Hepatitis/MASH

Top news of the day from across the health care landscape.

Sofosbuvir may help improve the kidney function of some patients with hepatitis C virus.

Mother-to-child transmission of hepatitis B virus remains high, despite an effective vaccine.

A bloated hepatitis C drug marketplace causes manufacturer to focus on hepatitis B.

Top news of the week from Specialty Pharmacy Times.

Determining how hepatitis C progresses is important when considering therapies and the associated costs for different patient groups.

This article highlights several key therapeutics areas with Vosevi that every pharmacist should know.

Accelerated fibrosis in women with a hepatitis C/HIV co-infection begins as early as pre-menopausal years.

Top news of the day from across the healthcare landscape.

Top news of the day from across the healthcare landscape.

A look at the top stories in pharmacy last week.

Patients with psychological and substance use problems are less likely to stay engaged in hepatitis C care.

Top news of the day from across the health care landscape.

Top news of the day from across the healthcare landscape.

The risk of developing liver cancer is similar with direct-acting antiviral drugs or interferon therapy for hepatitis C virus.

Treatments for hepatitis C, hemophilia, and cholesterol among specialty drugs approved for new indications this year.

West Virginia University program seeks to combat the spread of infectious diseases via injection drug use.

Baby boomer hepatitis C virus screening rates spiked when a prompt in their electronic health records reminded a primary care provider to recommend testing.

Patients who have received a transplant and are non-adherent to their medication regimens are more likely to experience graft failure and higher health care costs.

Hepatitis C elimination program screens more than 45K individuals in first 2 years of launch.

Triple drug regimen effectively cured patients with hepatitis C virus after they failed to respond to a combination of two oral direct-acting antivirals.

Elderly patients with hepatitis C are typically difficult to treat due to poor tolerability and suboptimal response to interferon-based regimens.

Top news of the week from Specialty Pharmacy Times.

Issues surrounding patents for curative drugs allow pharmaceutical companies to establish a market monopoly and charge astronomical prices.

An estimated 2.7 million Americans have hepatitis C, too many for specialists to be the sole provider of anti-HCV therapy.